Methods for prediction of anti-TNFα drug levels and autoantibody formation
AssigneePrometheus Biosiences, Inc.
InventorsSharat Singh, Venkateswarlu Kondragunta
Life of this patent
Estimating the term…
Abstract
In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNFα drug during the course of anti-TNFα drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNFα drug in a subject during the course of anti-TNFα drug therapy. Systems for predicting anti-TNFα drug levels and the likelihood of autoantibody formation during the course of anti-TNFα drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNFα drug therapy.
Claims10
A method for predicting a clinical outcome of a subject in response to therapy with an anti-TNFα drug, the method comprising measuring predictor variables comprising the level of IL12p40 or the level of IL-8, and the level of the anti-TNFα drug, in a sample obtained from the subject at least 2 weeks following induction with the anti-TNFα drug;
- comparing the predictor variables to a reference level for each predictor variable;
- predicting whether the subject will not have the clinical outcome in response to therapy with the anti-TNFα drug, based on the measured level of each predictor variable compared to the reference level for each predictor variable;
- and
- administering an anti-IL-8 drug or an anti-IL-12p40 drug to the subject when the subject is predicted to not have the clinical outcome in response to therapy with the anti-TNFα drug.
Dependencies are inferred from the claim text.